Previous in vitro and in vivo studies from our laboratory showed that progesterone (P 4 ), corticosterone (B), and testosterone (T) increase intracellular content and release of FSH in the anterior pituitary. Activin (Act) and inhibin (Inh) are structurally related proteins with antagonistic actions, as Act stimulates and Inh inhibits FSH secretion from the anterior pituitary. Together with follistatin (FS), a protein that bioneutralizes Act, they form an autocrine-paracrine loop in the anterior pituitary that tightly regulates FSH secretion. The objective of the present study was to test the hypothesis that P 4 , B, and T modulate this autocrine-paracrine loop to favor increased FSH secretion. If Act were to mediate steroid-induced FSH release, FS would be expected to block these effects. To test this interaction, cell cultures were prepared from anterior pituitaries of male and female rats, and treated with Act, B, P 4 , or T in the absence or presence of FS. Act, B, P 4 , and T increased FSH release; FS suppressed both basal and Act-and steroid-stimulated FSH release to approximately 50% below basal levels. Cell cultures from anterior pituitary of female rats were used to compare the interaction of incremental concentrations of FS on dose-related Act-and P 4 -stimulated FSH release. With increasing concentrations of Act, the FS-induced suppression of FSH release was attenuated and eventually abolished; in contrast, maximally stimulatory concentrations of P 4 did not fully overcome the FS-induced suppression of FSH release. The effects of P 4 , B, and Act in the presence and absence of estradiol on steady-state mRNA levels of FSH␤, Act␤ B , and FS were determined in primary pituitary cell cultures from metestrous female rats by reverse transcription-polymerase chain reaction. Whereas Act, P 4 , B increased FSH␤ mRNA levels, only Act raised the level of FS mRNA, and neither steroid increased Act␤ B mRNA. The results support the hypothesis that endogenous Act is a common mediator of the action of P 4 , B, and T in the rat primary anterior pituitary cell culture. We conclude that the stimulation of FSH release and intracellular content in the gonadotroph by P 4 , B, and T is mediated, in part, by Act and involves modulation of a tightly regulated Act/FS autocrine-paracrine loop.
INTRODUCTION
The central role of activin (Act), inhibin (Inh), and follistatin (FS) in regulating FSH synthesis and secretion is well established. These three proteins, along with hypothalamic factors and gonadal steroids, control pituitary function through endocrine and autocrine/paracrine actions. Act, Inh, and FS were isolated originally from ovary and identified subsequently in the anterior pituitary [1] [2] [3] [4] [5] [6] [7] . Act and Inh are dimeric proteins sharing a common ␤ subunit, with antagonistic functions in the anterior pituitary, stimulating (Act) and inhibiting (Inh) the expression of the FSH␤ subunit gene and FSH secretion [3, 7, 8] . FS is a heterogeneously glycosylated cysteine-rich, single-chain protein that is structurally unrelated to Act and Inh. FS bioneutralizes Act by binding to the ␤ subunit, which in turn prevents its binding to the Act receptor, and thereby indirectly suppresses FSH synthesis and secretion [9] [10] [11] .
The gonadal steroids, progesterone (P 4 ) in the female and testosterone (T) in the male, and the adrenal steroid corticosterone (B), increase FSH␤ subunit mRNA levels and FSH release in vivo and in vitro [12] [13] [14] [15] [16] [17] . In addition, a recent study from our laboratory demonstrated that the anti-progestin and anti-glucocorticoid RU-486 suppresses Act-induced FSH synthesis in vitro in the presence of estradiol (E 2 ) in anterior pituitary cell culture from female rats [18] . This finding suggests that there is cross-talk between Act-induced Smad signaling and progesterone receptor (PR) activation. In the present study, we tested the hypothesis that Act mediates the effects of the steroids P 4 , B, and T on FSH secretion in anterior pituitary cell culture by taking advantage of the ability of FS to bind and neutralize Act. Furthermore, by examining the effects of these steroids on mRNA levels of FSH␤, Act␤ B , and FS, we tested the hypothesis that P 4 or B mimic the effects of Act in modulating an Act-Inh-FS paracrine-autocrine loop in the anterior pituitary gonadotroph to favor increased FSH secretion.
MATERIALS AND METHODS

Materials
P 4 , B, T, and E 2 (Sigma Chemical Co., St. Louis, MO) were dissolved in absolute ethanol at 1000 times the desired final concentration; the corresponding concentration of ethanol (0.1%) was used as the vehicle. Recombinant human Act A, provided by the National Hormone and Pituitary Program (NHPP; Rockville, MD), was diluted with 0.05 M Tris-HCl (pH 7.4)-0.15 M NaCl from a 730 g/ml stock. Recombinant human FS, provided by the NHPP, was dissolved in H 2 O at a concentration of 100 g/ml, and 50-l (5 g) aliquots were lyophilized for storage. On subsequent occasions, single aliquots were reconstituted in H 2 O; the process of lyophilization and reconstitution led to an appreciable loss of activity. Media, sera, and all other reagents for cell culture were obtained from Life Technologies (Grand Island, NY).
Animals
Female and male Sprague-Dawley rats (Crl: CD [SD] BR-CD; 55-60 days old) were obtained from Charles River (Portage, MI). Animals were housed under a 14L:10D schedule, with lights-on at 0500 h, and were provided with standard rat chow and tap water ad libitum. In some ex-periments, in which metestrous donor rats were used, estrous cycles were monitored by daily vaginal cytology; only rats that exhibited at least two consecutive 4-day estrous cycles were included. Protocols were approved by the animal care and use committee of Northwestern University (Evanston, IL) and animals were maintained in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory animals.
Cell Dissociation and Culture
Animals were killed by decapitation at 0900-1000 h on metestrus or at random stages of the estrous cycle. Anterior pituitaries were collected and enzymatically dissociated as previously described [19] . The final cell pellet was suspended in Dulbecco's modified Eagle's medium containing 10% charcoal-adsorbed fetal bovine serum and 10 nM E 2 as indicated. Cells were plated in 24-well culture plates at a density of 3-5 ϫ 10 5 cells/2-cm 2 well in 1 ml medium for RIA or 12-well culture plates at a density of 1.5-2 ϫ 10 6 cells/3.8-cm 2 well in 2 ml medium for mRNA extraction. Primary cultures were incubated in a humidified atmosphere of 94% air-6% CO 2 at 37ЊC for 48 h. Media were collected, fresh media containing the test agents were then added, and incubation was continued for an additional 48 h. Incubation with each test agent was performed in quadruplicate.
RNA Extraction and Reverse Transcription
Total RNA was extracted by a single-step acid guanidinium thiocyanate-phenol-chloroform extraction (Tri Reagent; Molecular Research Center, Inc., Cincinnati, OH). Approximately 10 g total RNA for each sample was reverse-transcribed into cDNA with MMLV (Moloney murine leukemia virus) reverse transcriptase (5 U; Promega, Madison, WI), and random hexamers to prime the reaction, at 42ЊC for 75 min.
Polymerase Chain Reaction (PCR) Amplification
Three separate PCR protocols were used to detect mRNA for FSH␤, Act␤ B , and FS. For FSH␤, a 384-base pair (bp) sequence was amplified using the oligonucleotide primers 5Ј-ATGAAGTCGATCCAGCTTTG-3Ј (sense) and 5Ј-TCATTTCACCGAAGGAGCAG-3Ј (antisense) [20] . A 306-bp fragment of Act ␤ B was amplified with sense 5Ј-TATGTCCTGGAGAAGGGCAGC-3Ј and antisense 5Ј-GCGATGTCTGCTATCGCCCAG-3Ј primers. For FS, the sense, 5Ј-TCTGCCAATTCATGGAAGAC-3Ј and antisense 5Ј-CTGGAGTAATCACACCATC-3Ј primers were used to amplify a 596-bp sequence [20] . For the FSH␤ and Act␤ B PCRs, primers (5Ј-CCATCCACCCGGCAGCCG-3Ј and 5Ј-GTAGTCGACAGAGAGCCT-3Ј) that amplified a 514-bp cDNA for ␣-tubulin [20] were included to control for reaction efficiency and variations in concentrations of mRNA in the reverse transcription (RT) reaction. Primers (5Ј-CTGAAGGTCAAAGGGAATGTG-3Ј and 5Ј-GGACA-GAGTCTTGATGATCTC-3Ј) that amplified a 191-bp cDNA for ribosomal protein L19 (RPL19) were used in the PCR amplification of FS mRNA [21] . PCR amplifications were performed in a single step for FSH␤ and in two steps for Act␤ B and FS to obtain similar intensities for the product of interest and the more abundant internal control. For the one-step PCR for FSH␤, the reaction mixture contained 1.25 mM MgCl 2 , 0.2 mM of each of the four dNTPs, 12.5 pmol of each primer, 0.5 Ci [ 32 P]dCTP (Amersham, Arlington Heights, IL), single-strength Taq polymerase buffer, and 1.25 U Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, CT) in a final volume of 25 l. For the two-step protocol, the first reaction mixture contained 2 mM MgCl 2 , 0.2 mM of each of the four dNTPs, 12.5 pmol of primer, 0.5 Ci [ 32 P]dCTP, single-strength Taq polymerase buffer, and 1.25 U Taq DNA polymerase in a final volume of 25 l, overlaid with 45 l mineral oil. After the appropriate number of cycles with the first set of primers, 20 l of a cocktail containing 12.5 pmol each of the second set of primers and 1.25 U additional Taq DNA polymerase was added in single-strength PCR buffer with 2 mM MgCl 2 for the remaining cycles. Amplifications were carried out for successive cycles of denaturation at 94ЊC for 30 sec, annealing at 55ЊC for 45 sec, and extension at 72ЊC for 45 sec, with an initial denaturation at 94ЊC for 5 min and a final extension at 72ЊC for 10 min. The optimal number of cycles, determined experimentally to yield a linear relationship between signal intensity and input cDNA, and an exponential one with respect to cycle number was 23 for FSH␤, 26 for Act␤ B , and 29 for FS. Amplifications with the primers for ␣-tubulin and RPL19 were performed for 23 and 25 cycles, respectively. Radiolabeled PCR products were separated by electrophoresis on 6% nondenaturing polyacrylamide gels in Tris borate-EDTA buffer. Signal intensity was quantified using PhosphorImage (Molecular Dynamics, Sunnyvale, CA).
FSH Release and Cell Content
Culture media were sampled for FSH concentration at 48 and 96 h. At the end of the incubation, as indicated, cell monolayers were lysed in 1 ml Dulbecco's PBS containing 0.3% BSA and 1% each of Triton X-100 and sodium deoxycholate for determination of intracellular hormone content as indicated. All media and lysates were stored at Ϫ20ЊC until RIA.
Hormone Assays
FSH concentration in the culture media and cell lysates was determined by a double-antibody RIA described previously [22] , with reagents supplied by the NHPP.
Statistical Analysis
All data presented are the mean Ϯ SE of quadruplicate incubations from a single representative experiment. The effects of Act and steroids in combination with FS (E 2 in experiment 5) were evaluated by two-way ANOVA. When these treatments were found to produce significant overall effects and interactions, data obtained in the absence or presence of FS, or at each level of Act or P 4 in experiments 3 and 4, were reanalyzed by one-way ANOVA to allow post-hoc comparisons of individual treatment groups. Posthoc comparisons of the effects of test agents were performed using the Neuman-Keuls test. P values of Ͻ 0.05 were considered significant.
Experimental Protocols Experiment 1. Anterior pituitaries from female rats (n ϭ 8) at random stages of the estrous cycle were enzymatically dissociated, and cells were plated. The culture medium contained 10 nM E 2 throughout the 96-h incubation. After preincubation for 48 h, cells were incubated with Act (10 ng/ ml), B (1 M), or P 4 (1 M), or combinations of Act, B, and P 4 without or with FS (20 ng/ml) for an additional 48 h. Media were collected, and cell monolayers were lysed. FSH in the medium and intracellular FSH content were determined by RIA. Experiment 2. Anterior pituitaries of male rats (n ϭ 4) were collected and dissociated, and cells were plated. After incubation for 48 h, cells were treated with Act (10 ng/ml), B (1 M), or T (10 nM) without or with FS (50 ng/ml; the concentration of FS was increased compared to that used in experiment 1 to compensate for the loss of activity due to lyophilization and reconstitution) for an additional 48 h. Media were collected, and FSH concentration was determined by RIA. Experiment 3. Anterior pituitaries from cycling female rats (n ϭ 10) were collected at 0900 h on the morning of metestrus and dissociated, and cells were plated in the presence of E 2 (10 nM). At 48 h, media were replaced with fresh media containing E 2 , Act (3, 10, 30, or 100 ng/ml), and FS (20, 50, or 100 ng/ml). At 96 h, media were collected, and FSH was measured by RIA. Experiment 4. Anterior pituitaries (n ϭ 12) were collected from female rats at random stages of the estrous cycle and dissociated, and cells were plated in the presence of 10 nM E 2 . After 48 h, media were changed, and cells were treated with E 2 , P 4 (1, 10, 100, or 1000 nM), and FS (20, 50, or 100 ng/ml) for an additional 48 h. FSH released into the media was measured by RIA.
Experiment 5. Anterior pituitaries from cycling female rats (nϭ21) were collected at 0900 h on the morning of metestrus and dissociated, and cells were plated. At 48 h, cells were treated with P 4 (100 nM), B (1.7 M), or Act (100 ng/ml); concentrations were chosen to ensure maximal responses. Duplicate sets of primary cultures were incubated with these agents in the absence or the presence of 10 nM E 2 . At 96 h, media were collected, and FSH was assayed by RIA. Messenger RNA levels were analyzed by semiquantitative RT-PCR for FSH␤, FS, and Act␤ B .
RESULTS
Primary anterior pituitary cells from female rats at random stages of the estrous cycle were incubated with Act, B, or P 4 , or combinations of Act, B, and P 4 for 48 h ( Fig.  1; experiment 1) . In all cases, FSH release (ng/ml) in the absence of FS was significantly increased above the basal level (P Ͻ 0.0001 for Act/steroid treatment overall). Act in combination with B or P 4 had a significantly greater effect than Act, B, or P 4 alone (P Ͻ 0.05). B and P 4 together had no greater effect than either steroid alone. Coincubation with 20 ng/ml FS significantly inhibited FSH release in all treatment groups to a level less than 40% of basal release. Analysis by two-way ANOVA showed the effect of FS to be highly significant overall (P Ͻ 0.0001), with a significant interaction between FS and Act/steroid treatment (P Ͻ 0.0001). A similar, but less profound effect was seen on FSH intracellular content in this and the subsequent experiments (data not shown).
Treatment with Act, B, or T elicited a similar FSH response in anterior pituitary cell culture from male rats ( Fig.  2; experiment 2) . Act, B, or T significantly increased FSH release (P Ͻ 0.01, 0.05, and 0.001, respectively), although to a lesser degree than in anterior pituitary cell cultures from female rats. Coincubation with 50 ng/ml FS significantly suppressed FSH release to approximately 50% below basal (P Ͻ 0.0001), and there was a significant interaction between FS and the stimulators (P ϭ 0.001).
The effects of incremental concentrations of FS on Actor P 4 -enhanced FSH release were compared in anterior pituitary cell cultures from female rats to determine whether the effects of the two stimulators were qualitatively similar (experiments 3 and 4). Act increased FSH release in a dosedependent manner during 48 h of incubation (Fig. 3) . The highest concentration of Act that we used did not appear to be maximally stimulatory. With increasing concentrations of Act, the FS-induced suppression of FSH was attenuated and eventually abolished. At the lowest concentration of Act tested, all concentrations of FS were inhibitory, whereas at the highest concentration of Act, all concentrations of FS were ineffective in suppressing FSH release. The effects of both Act and FS on FSH release were highly significant (P Ͻ 0.0001) and there was a highly significant interaction between the treatments (P Ͻ 0.0001). P 4 at concentrations ranging from 1 nM to 1000 nM increased FSH release (Fig. 4) ; the effect of 100 nM P 4 was Figure 3 . maximal, i.e., not significantly different from that of 1000 nM. Addition of FS suppressed FSH release in a concentration-dependent manner at all concentrations of P 4 . As in experiment 3, the effects of both the stimulator and FS were highly significant, as was the interaction between the treatments (P Ͻ 0.0001). The interaction of FS with P 4 , however, differed markedly from that with Act, as even the highest concentration of P 4 did not overcome the FS-induced suppression of FSH release.
To determine whether the steroids modulated Act and FS mRNA levels to favor increased FSH synthesis, FSH␤, Act ␤ B , and FS mRNA levels were analyzed by semiquantitative RT-PCR (experiment 5). Primary anterior pituitary cell cultures from female rats were incubated with Act, B, or P 4 in the presence or absence of E 2 for 48 h. Act, B, or P 4 significantly increased FSH release (P Ͻ 0.0001; Fig.  5A ); the effect of E 2 was also significant (P ϭ 0.001); there was not, however, a significant interaction between the treatments. Act and B, but not P 4 , significantly increased FSH␤ mRNA levels (Fig. 5B) in the presence or absence of E 2 (P Ͻ 0.001), consistent with previous results from our laboratory and others [19, 23] . Treatment with E 2 significantly lowered FSH␤ subunit mRNA (P ϭ 0.0001). Act increased FS mRNA significantly only in the absence of E 2 (P Ͻ 0.01; Fig. 5C ); however, neither B nor P 4 had a significant effect on FS mRNA. None of the treatments significantly affected Act␤ B mRNA levels (data not shown).
DISCUSSION
Several lines of evidence indicate that B, P 4 , or T increase FSH␤ mRNA and FSH intracellular content and release in vitro [12] [13] [14] [15] [16] [17] 19] . The present study examined the possible interaction between Act and steroids in the anterior pituitary. FS was able to completely suppress steroid-induced FSH release to a level 50-70% below basal. This finding suggests that Act mediates enhancement of FSH release by B, P 4 , and T. Whereas Act at high concentrations overcame the FS-induced suppression of FSH release, P 4 at high concentrations did not abolish the suppressive effects of FS. While the full range of effective concentrations (1-1000 nM) for P 4 was tested, a maximally effective concentration of Act was not reached in the present study because of limited availability of recombinant human Act. The effects of P 4 were probably limited because of saturation of the PR and could not, therefore, reach the effect of the highest concentration of exogenous Act tested. Nonetheless, the lowest concentration of FS significantly suppressed the response to maximally effective concentrations of P 4 , while that same concentration of FS had no effect on the responses to the three highest concentrations of Act. Hence, P 4 -induced FSH release was highly susceptible to suppression by FS. The effect of FS implies accumulation and action of endogenous Act underlying steroid-enhanced FSH release. A recent study by Graham et al. [24] , showing that the L␤T2 gonadotroph cell line is able to express FSH␤ mRNA only when Act is added to the cultures, underscores the central role of Act to FSH biosynthesis.
Neither B nor P 4 affected FS mRNA levels during a 48-h incubation in vitro, while under the same conditions, Act up-regulated FS mRNA levels. Thus, B and P 4 at concentrations that increased release and intracellular content of FSH did not mimic the effects of Act on FS mRNA, suggesting either that the steroids do not act solely through accumulation of endogenous Act in stimulating FSH secretion or that they were not present in sufficient concentrations to activate FS gene transcription. Our failure to demonstrate increased Act␤ B mRNA levels in the pituitary cell culture upon addition of the steroids does not rule out an intermediary role of endogenous Act in their action on FSH secretion; inappropriate timing and concentrations may account for this finding.
Few previous studies have addressed the effects of the gonadal and adrenal steroids on the Act pathway in rat anterior pituitary cell culture. Miyake et al. [13] demonstrated that the effects of P 4 or T were additive with those of exogenous Act A in stimulating FSH secretion from female rat anterior pituitary cell culture, as confirmed in the present study. In a different study, T increased Act␤ B mRNA and suppressed FS mRNA in anterior pituitary cell culture from male rats [25] . To date, no data are available on the interaction between glucocorticoids and Act in the gonadotroph.
The present results in conjunction with our previous finding that RU-486 suppresses Act-induced FSH release suggest that there may be cross-talk between Act-mediated and steroid-mediated pathways in the anterior pituitary. In a recent study, Yanagisawa et al. [26] demonstrated similar cross-talk between transforming growth factor-␤ (TGF␤)-mediated and vitamin D-mediated signaling. The TGF␤ signal transduction pathway, like that of Act, utilizes Smad proteins, whereas vitamin D, like P 4 , B, and T, binds to a nuclear receptor. Specifically, Smad 3, activated by TGF␤, was found to form a complex with a member of the steroid receptor coactivator-1 protein family and thus enhance the actions of vitamin D. Likewise, it is possible that coactivators recruited by E 2 bind to Act-activated, phosphorylated Smad proteins and associate with transcriptional complexes activated by PR in the nucleus. Moreover, the FSH␤ promoter area contains P 4 response elements (PRE) [27, 28] as well as an AP-1 site [29] . The promoter area of the early intermediate gene junB, which activates AP-1 sites, is a target for Act and contains an Act response element [30, 31] . In the presence of E 2 , simultaneous activation of the PRE and AP-1 sites on the FSH␤ promoter may be required to promote transcriptional activation of the FSH␤ gene.
Our results suggest that in the gonadotroph, the steroids B, P 4 , and T increase FSH release in part by modulating the Act-FS-Inh autocrine paracrine loop. We conclude that endogenous Act contributes to the stimulatory action of steroids on FSH secretion.
